Charles Carter

Charles Carter

Director of Finance/CFO at OVID THERAPEUTICS INC.

Net worth: 26 900 $ as of 30/06/2026

59 year
Health Technology
Consumer Services
Technology Services

Profile

Charles R.
Carter
is Chief Financial & Accounting Officer, Secretary at Ovid Therapeutics, Inc. since 2026.
Former roles include Chief Financial Officer, Secretary & Treasurer at CERo Therapeutics Holdings, Inc. in 2024; Chief Financial Officer, Secretary & Treasurer at Morphic Medical, Inc. from 2018 to 2021; Chief Financial Officer at The Guild For Human Services from 2015 to 2018; Chief Financial Officer & Secretary at iCAD, Inc. from 2021 to 2022; Chief Financial Officer at Intelligent Medical Devices, Inc.; Principal at Adnexus; Partner at Mercer Management Consulting, Inc.; Chief Financial Officer at Aeris Therapeutics LLC; and Senior Director-Financial Planning & Analysis at Shire Human Genetic Therapies, Inc. Education includes undergraduate studies at Colgate University and graduate studies including an MBA at The University of Chicago.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
06/07/2026 10,000 ( 0.01% ) 26 900 $ 30/06/2026

Charles Carter active positions

CompaniesPositionStart
OVID THERAPEUTICS INC. Director of Finance/CFO 06/07/2026

Former positions of Charles Carter

CompaniesPositionEnd
ICAD Director of Finance/CFO 20/05/2022
GI DYNAMICS, INC. Director of Finance/CFO 01/04/2021
Director of Finance/CFO 01/02/2018
Corporate Officer/Principal -
See the detail of Charles Carter's experience

Training of Charles Carter

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

15

1st degree connections

11

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies11

Health Technology

Health Technology

Health Technology

Technology Services

Commercial Services

Health Technology

Consumer Services

Consumer Services

Health Technology

Health Technology

Health Services

  1. Stock Market
  2. Insiders
  3. Charles Carter